Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Hirschfield, Gideon M.Shiffman, Mitchell L.Gulamhusein, AliyaKowdley, Kris V.Vierling, John M.Levy, CynthiaKremer, Andreas E.Zigmond, EhudAndreone, PietroGordon, Stuart C.Bowlus, Christopher L.Lawitz, Eric J.Aspinall, Richard J.Pratt, Daniel S.Raikhelson, KarinaGonzalez-Huezo, Maria S.Heneghan, Michael A.Jeong, Sook-HyangGuevara, Alma L. Ladrón deMayo, Marlyn J.Dalekos, George N.Drenth, Joost P. H.Janczewska, EwaLeggett, Barbara A.Nevens, FrederikVargas, VictorZuckerman, EliCorpechot, ChristopheFassio, EduardoHinrichsen, HolgerInvernizzi, PietroTrivedi, Palak J.Forman, LisaJones, David E. J.Ryder, StephenSwain, Mark G.Steinberg, AlexandraBoudes, Pol F.Choi, Yun-JungMcWherter, Charles A.Papp, Mária2024-04-242024-04-242023Hepatology. -78 : 2 (2023), p. 397-415. -Hepatology. - 0270-91390270-9139https://hdl.handle.net/2437/369218Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM120677OrvostudományokKlinikai orvostudományokhttps://journals.lww.com/10.1097/HEP.0000000000000395szerzőhttp://dx.doi.org/10.1097/HEP.00000000000003952024-04-2400103221520002485165221969